vs
LivaNova PLC(LIVN)とRevolve Group, Inc.(RVLV)の財務データ比較。上の社名をクリックして会社を切り替えられます
LivaNova PLCの直近四半期売上が大きい($360.9M vs $324.4M、Revolve Group, Inc.の約1.1倍)。LivaNova PLCの純利益率が高く(8.6% vs 5.7%、差は2.8%)。LivaNova PLCの前年同期比売上増加率が高い(12.1% vs 10.4%)。LivaNova PLCの直近四半期フリーキャッシュフローが多い($50.2M vs $-13.3M)。過去8四半期でLivaNova PLCの売上複合成長率が高い(10.6% vs 9.5%)
LivaNova PLCは医療機器メーカーで、イギリスに本社を置いています。心臓外科手術用機器と神経調整用機器の開発を主な事業とし、2015年に米国のサイバロニクス社とイタリアのソリン社が27億米ドルで合併して設立されました。現在はNASDAQに上場し、証券コードはLIVNです。
Revolve Theatre Companyはテムズ河畔ヘンリーを拠点とする劇団で、政治的なテーマの作品やシェイクスピア劇を専門に制作・上演しており、オリバー・デンチ、ジョー・モリス、トム・スミスの3人が所有しています。
LIVN vs RVLV — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | ||
|---|---|---|
| 売上 | $360.9M | $324.4M |
| 純利益 | $30.9M | $18.6M |
| 粗利率 | 65.2% | 53.3% |
| 営業利益率 | 11.8% | 6.3% |
| 純利益率 | 8.6% | 5.7% |
| 売上前年比 | 12.1% | 10.4% |
| 純利益前年比 | -44.7% | 50.4% |
| EPS(希薄化後) | $0.57 | $0.27 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $360.9M | $324.4M | ||
| Q3 25 | $357.8M | $295.6M | ||
| Q2 25 | $352.5M | $309.0M | ||
| Q1 25 | $316.9M | $296.7M | ||
| Q4 24 | $321.8M | $293.7M | ||
| Q3 24 | $318.1M | $283.1M | ||
| Q2 24 | $318.6M | $282.5M | ||
| Q1 24 | $294.9M | $270.6M |
| Q4 25 | $30.9M | $18.6M | ||
| Q3 25 | $26.8M | $21.2M | ||
| Q2 25 | $27.2M | $10.2M | ||
| Q1 25 | $-327.3M | $11.8M | ||
| Q4 24 | $55.9M | $12.3M | ||
| Q3 24 | $33.0M | $11.0M | ||
| Q2 24 | $16.3M | $15.4M | ||
| Q1 24 | $-41.9M | $10.9M |
| Q4 25 | 65.2% | 53.3% | ||
| Q3 25 | 68.4% | 54.6% | ||
| Q2 25 | 67.8% | 54.1% | ||
| Q1 25 | 69.7% | 52.0% | ||
| Q4 24 | 68.2% | 52.5% | ||
| Q3 24 | 70.8% | 51.2% | ||
| Q2 24 | 68.7% | 54.0% | ||
| Q1 24 | 70.3% | 52.3% |
| Q4 25 | 11.8% | 6.3% | ||
| Q3 25 | 15.1% | 7.1% | ||
| Q2 25 | 15.4% | 5.8% | ||
| Q1 25 | 15.3% | 5.0% | ||
| Q4 24 | 11.5% | 3.9% | ||
| Q3 24 | 11.2% | 5.0% | ||
| Q2 24 | 12.6% | 5.8% | ||
| Q1 24 | 5.5% | 3.4% |
| Q4 25 | 8.6% | 5.7% | ||
| Q3 25 | 7.5% | 7.2% | ||
| Q2 25 | 7.7% | 3.3% | ||
| Q1 25 | -103.3% | 4.0% | ||
| Q4 24 | 17.4% | 4.2% | ||
| Q3 24 | 10.4% | 3.9% | ||
| Q2 24 | 5.1% | 5.4% | ||
| Q1 24 | -14.2% | 4.0% |
| Q4 25 | $0.57 | $0.27 | ||
| Q3 25 | $0.49 | $0.29 | ||
| Q2 25 | $0.50 | $0.14 | ||
| Q1 25 | $-6.01 | $0.16 | ||
| Q4 24 | $1.04 | $0.18 | ||
| Q3 24 | $0.60 | $0.15 | ||
| Q2 24 | $0.30 | $0.21 | ||
| Q1 24 | $-0.78 | $0.15 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | ||
|---|---|---|
| 現金・短期投資手元流動性 | $635.6M | $292.3M |
| 総負債低いほど良い | $376.1M | — |
| 株主資本純資産 | $1.2B | $512.5M |
| 総資産 | $2.6B | $765.0M |
| 負債/資本比率低いほどレバレッジが低い | 0.31× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $635.6M | $292.3M | ||
| Q3 25 | $646.1M | $315.4M | ||
| Q2 25 | $593.6M | $310.7M | ||
| Q1 25 | $738.4M | $300.8M | ||
| Q4 24 | $428.9M | $256.6M | ||
| Q3 24 | $346.4M | $252.8M | ||
| Q2 24 | $329.2M | $244.7M | ||
| Q1 24 | $309.2M | $273.4M |
| Q4 25 | $376.1M | — | ||
| Q3 25 | $434.5M | — | ||
| Q2 25 | $430.6M | — | ||
| Q1 25 | $628.2M | — | ||
| Q4 24 | $627.0M | — | ||
| Q3 24 | $625.5M | — | ||
| Q2 24 | $624.5M | — | ||
| Q1 24 | $623.8M | — |
| Q4 25 | $1.2B | $512.5M | ||
| Q3 25 | $1.2B | $490.2M | ||
| Q2 25 | $1.1B | $468.6M | ||
| Q1 25 | $1.0B | $453.4M | ||
| Q4 24 | $1.3B | $437.8M | ||
| Q3 24 | $1.3B | $420.8M | ||
| Q2 24 | $1.2B | $405.8M | ||
| Q1 24 | $1.2B | $389.9M |
| Q4 25 | $2.6B | $765.0M | ||
| Q3 25 | $2.6B | $751.3M | ||
| Q2 25 | $2.5B | $722.9M | ||
| Q1 25 | $2.6B | $713.9M | ||
| Q4 24 | $2.5B | $665.5M | ||
| Q3 24 | $2.5B | $670.9M | ||
| Q2 24 | $2.5B | $657.8M | ||
| Q1 24 | $2.5B | $650.0M |
| Q4 25 | 0.31× | — | ||
| Q3 25 | 0.38× | — | ||
| Q2 25 | 0.38× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | 0.51× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | ||
|---|---|---|
| 営業キャッシュフロー直近四半期 | $82.4M | $-10.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $50.2M | $-13.3M |
| FCFマージンFCF / 売上 | 13.9% | -4.1% |
| 設備投資強度設備投資 / 売上 | 8.9% | 1.0% |
| キャッシュ転換率営業CF / 純利益 | 2.67× | -0.55× |
| 直近12ヶ月FCF直近4四半期 | $173.3M | $48.0M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $82.4M | $-10.2M | ||
| Q3 25 | $85.1M | $11.8M | ||
| Q2 25 | $62.9M | $12.6M | ||
| Q1 25 | $24.0M | $45.1M | ||
| Q4 24 | $78.7M | $3.9M | ||
| Q3 24 | $51.0M | $9.1M | ||
| Q2 24 | $43.4M | $-24.7M | ||
| Q1 24 | $10.0M | $38.4M |
| Q4 25 | $50.2M | $-13.3M | ||
| Q3 25 | $62.2M | $7.5M | ||
| Q2 25 | $47.8M | $10.4M | ||
| Q1 25 | $13.2M | $43.4M | ||
| Q4 24 | $68.3M | $2.1M | ||
| Q3 24 | $32.8M | $8.0M | ||
| Q2 24 | $31.2M | $-25.7M | ||
| Q1 24 | $3.6M | $36.7M |
| Q4 25 | 13.9% | -4.1% | ||
| Q3 25 | 17.4% | 2.5% | ||
| Q2 25 | 13.6% | 3.4% | ||
| Q1 25 | 4.2% | 14.6% | ||
| Q4 24 | 21.2% | 0.7% | ||
| Q3 24 | 10.3% | 2.8% | ||
| Q2 24 | 9.8% | -9.1% | ||
| Q1 24 | 1.2% | 13.5% |
| Q4 25 | 8.9% | 1.0% | ||
| Q3 25 | 6.4% | 1.5% | ||
| Q2 25 | 4.3% | 0.7% | ||
| Q1 25 | 3.4% | 0.6% | ||
| Q4 24 | 3.2% | 0.6% | ||
| Q3 24 | 5.7% | 0.4% | ||
| Q2 24 | 3.8% | 0.4% | ||
| Q1 24 | 2.2% | 0.6% |
| Q4 25 | 2.67× | -0.55× | ||
| Q3 25 | 3.18× | 0.56× | ||
| Q2 25 | 2.32× | 1.24× | ||
| Q1 25 | — | 3.82× | ||
| Q4 24 | 1.41× | 0.32× | ||
| Q3 24 | 1.55× | 0.83× | ||
| Q2 24 | 2.65× | -1.60× | ||
| Q1 24 | — | 3.53× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
RVLV
| Fashion Apparel | $155.1M | 48% |
| Dresses | $76.4M | 24% |
| Handbags Shoes And Accessories | $67.6M | 21% |
| Beauty | $20.3M | 6% |
| Manufactured Product Other | $5.0M | 2% |
| Breakage On Store Credit And Gift Cards | $900.0K | 0% |